These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7805371)

  • 61. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
    Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
    Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
    Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
    Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
    Hümpel M; Täuber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B; Seifert W; Schütt B
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon).
    Ismail MT
    Malays J Reprod Health; 1994 Jun; 12(1):43-8. PubMed ID: 12320338
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The current status of oral contraceptive clinical development in Japan.
    Kuwabara Y
    Int J Fertil; 1989; 34 Suppl():18-20. PubMed ID: 2576251
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet).
    Kornaat H; Geerdink MH; Klitsie JW
    Contraception; 1992 Feb; 45(2):119-27. PubMed ID: 1559335
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations.
    Stanczyk FZ; Archer DF
    Contraception; 2014 Apr; 89(4):242-52. PubMed ID: 24485094
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence.
    Venturoli S; Porcu E; Gammi L; Fabbri R; Paradisi R; Flamigni C; Patrono D; Capelli M; Paoletti C
    Acta Eur Fertil; 1988; 19(3):129-34. PubMed ID: 2976224
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen.
    Carr BR
    Int J Fertil Menopausal Stud; 1993; 38(5):274-9. PubMed ID: 8298666
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene in Latin American women.
    Bassol S; Alvarado G; Arreola RG; Celis-Gonzalez C; Peña EP; Flores JG; Ahued JR; Ricalde RL; Lopez CR; Prieto G; Gurucharri C; Heredia MG; Ortiz OC; Percossi G; Figueroa Casas PR; Botto E; Tozzini RI; Botti G; Nuñez de Pierro A; Fernandez M; Lastreto E; Nañez M; Carneiro de Oliveira H; Diogenes Holanda Yazlle ME; Silva J; Salazar G; Gomez J; Penagos G; Cifuentes R; Torres LA; Reyes-Marquez R; Albrecht G
    Contraception; 2003 May; 67(5):367-72. PubMed ID: 12742559
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Aug; 64(2):99-105. PubMed ID: 11704086
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene.
    Düsterberg B; Ellman H; Müller U; Rowe E; Mühe B
    Gynecol Endocrinol; 1996 Feb; 10(1):33-9. PubMed ID: 8737190
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial.
    Weber-Diehl F; Unger R; Lachnit U
    Contraception; 1992 Jul; 46(1):19-27. PubMed ID: 1424620
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
    Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
    Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.